Alnylam Pharmaceuticals Former President Barry Greene's 2020 pay jumps 232% to $10M
Alnylam Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: April 2, 2021
Alnylam Pharmaceuticals reported fiscal year 2020 executive compensation information on April 2, 2021.
In 2020, six executives at Alnylam Pharmaceuticals received on average a compensation package of $4.8M, a 16% increase compared to previous year.
Average pay of disclosed executives at Alnylam Pharmaceuticals
Barry E. Greene, Former President, received $10M in total, which increased by 232% compared to 2019. 80% of Greene's compensation, or $8.3M, was in option awards. Greene also received $376K in non-equity incentive plan, $484K in salary, $458K in stock awards, as well as $717K in other compensation.
For fiscal year 2020, the median employee pay was $233,341 at Alnylam Pharmaceuticals. Therefore, the ratio of Barry E. Greene's pay to the median employee pay was 44 to one.
John M. Maraganore, Chief Executive Officer, received a compensation package of $7.8M, which increased by 7% compared to previous year. 73% of the compensation package, or $5.7M, was in option awards.
Yvonne L. Greenstreet, Chief Operating Officer, earned $3M in 2020, a 7% decrease compared to previous year.
Akshay K. Vaishnaw, President, Research and Development, received $2.9M in 2020, which decreases by 7% compared to 2019.
Jeffrey V. Poulton, Chief Financial Officer, earned $2.5M in 2020, a 58% decrease compared to previous year.
Laurie B. Keating, Chief Legal Officer, received $2.4M in 2020, which increases by 1% compared to 2019.
Related executives
John Maraganore
Alnylam Pharmaceuticals
Chief Executive Officer
Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Operating Officer
Akshay Vaishnaw
Alnylam Pharmaceuticals
President, Research and Development
Jeffrey Poulton
Alnylam Pharmaceuticals
Chief Financial Officer
Laurie Keating
Alnylam Pharmaceuticals
Chief Legal Officer
Barry Greene
Alnylam Pharmaceuticals
Former President
You may also like
Source: SEC filing on April 2, 2021.